Compare Broadcom Inc (AVGO) vs Crispr Therapeutics AG (CRSP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Broadcom Inc vs Crispr Therapeutics AG — how do they compare? Broadcom Inc trades at $419.54 (market cap $1.98T), while Crispr Therapeutics AG trades at $53.81 (market cap $5.23B). The key difference: Broadcom Inc is far larger — about 378.6× Crispr Therapeutics AG's market cap, and Broadcom Inc pays a 0.62% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| AVGO | CRSP | |
|---|---|---|
Market Cap | $1.98T | $5.23B |
Sector | Technology | Health |
52-Week High | $481.57 | $76.78 |
52-Week Low | $289.60 | $44.34 |
Enterprise Value | $2.02T | $3.65B |
Dividend Yield | 0.62% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Broadcom (AVGO) trades at $422.4, down 1.25% on the day, but maintains a bullish technical trend with strong support at $418. The company reported robust earnings, beating estimates for three consecutive quarters, with Q1 2026 EPS of $2.44 exceeding the $2.40 forecast. Revenue growth accelerated to $63.89 billion in 2025, up from $51.6 billion in 2024, while net income surged to $23.13 billion. Valuation multiples remain elevated with a P/E of 69.23, reflecting high investor expectations for AI-driven growth.
Outlook remains positive given strong AI revenue projections exceeding $100 billion by 2027, but high valuation and dependence on a few large customers pose risks. Analyst consensus is overwhelmingly bullish with 86% buy ratings and a $510.21 price target, suggesting 21% upside. Competitive pressures in the semiconductor space and macroeconomic volatility are key watchpoints for investors.
CRISPR Therapeutics (CRSP) trades at $53.51, down slightly by 0.02% today. The stock shows bullish technical signals with strong support at $53 and resistance at $54. Fundamentally, the company reports widening losses with a net income margin of -4,101.26% in 2025, though Q2 2026 earnings beat expectations. Analyst sentiment remains positive with a consensus price target of $82.67, driven by robust CASGEVY sales growth and pipeline advancements.
Outlook: CRSP offers significant upside potential from gene-editing therapeutics, but high cash burn and negative profitability pose risks. Investment appeal hinges on successful clinical trials and market expansion of approved therapies, balanced against financial sustainability concerns in a competitive biotech landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Broadcom Inc
Broadcom--the combined entity of Broadcom and Avago--boasts a highly diverse product portfolio across an array of end markets. Avago focused primarily on radio frequency filters and amplifiers used in high-end smartphones, such as the Apple iPhone and Samsung Galaxy devices, in addition to an assortment of solutions for wired infrastructure, enterprise storage, and industrial end markets. Legacy Broadcom targeted networking semiconductors, such as switch and physical layer chips, broadband products (such as television set-top box processors), and connectivity chips that handle standards such as Wi-Fi and Bluetooth. The company has acquired Brocade, CA Technologies, Symantec's enterprise security business, and has a pending deal to acquire VMware to bolster its offerings in software.
Read more on AVGO →About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →
